| Identification | Back Directory | [Name]
Benzoic acid,4-[4-[(2-bromoacetyl)amino]butyl]- | [CAS]
10161-87-2 | [Synonyms]
KRA-533
Benzoic acid,4-[4-[(2-bromoacetyl)amino]butyl]-
KRA-533，Benzoic acid,4-[4-[(2-bromoacetyl)amino]butyl]- | [Molecular Formula]
C13H16BrNO3 | [MOL File]
10161-87-2.mol | [Molecular Weight]
314.17 |
| Chemical Properties | Back Directory | [Boiling point ]
530.4±45.0 °C(Predicted) | [density ]
1.428±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
Solid | [pka]
4.34±0.10(Predicted) | [color ]
White to off-white | [InChI]
1S/C13H16BrNO3/c14-9-12(16)15-8-2-1-3-10-4-6-11(7-5-10)13(17)18/h4-7H,1-3,8-9H2,(H,15,16)(H,17,18) | [InChIKey]
WZQJLTLURXNPQG-UHFFFAOYSA-N | [SMILES]
O=C(O)C1=CC=C(CCCCNC(CBr)=O)C=C1 |
| Hazard Information | Back Directory | [Uses]
KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells. | [Biological Activity]
KRA-333 is a potent and selective KRAS agonist th at binds directly to the GTP/GDP binding pocket of KRAS preventing the cleavage of GTP into GDP and caucusing accumulation of activated GTP-KRAS and suppression of cell growth. KRA-333 promotes apoptosis and autophagic cell death of cancer cells and inhibits growth of mutant KRAS lung cancer in xenografts mice model. | [in vivo]
KRA-533 (0~30 mg/kg; i.p.; 28 days) suppresses tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induces apoptosis and autophagy in tumor tissues in a dose-dependent manner[1].
?
KRA-533 shows optimal therapeutic index between 7.5 mg/kg and 30 mg/kg doses[1]. | Animal Model: | Nu/Nu nude mice (mutant KRAS xenografts)[1] | | Dosage: | 0~30 mg/kg | | Administration: | i.p.; 28 days | | Result: | Suppressed tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induced apoptosis and autophagy in tumor tissues in a dose-dependent manner.
|
| [References]
[1] Xu K, et al. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy [published correction appears in Mol Cancer. 2020 May 20;19(1):93]. Mol Cancer. 2019;18(1):85. Published 2019 Apr 10. DOI:10.1186/s12943-019-1012-4 |
|
|